Injection of vessel-derived stem cells prevents dilated cardiomyopathy and promotes angiogenesis and endogenous cardiac stem cell proliferation in mdx/utrn-/- but not aged mdx mouse models for duchenne muscular dystrophy

Stem Cells Translational Medicine

Volumn 2, Issue 1, 2013, Pages 68-80

  Chun, Ju Lan ^a   O'Brien, Robert ^a   Song, Min Ho ^a   Wondrasch, Blake F ^a   Berry, Suzanne E ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Angiogenesis; Cardiac; Cell transplantation; Cellular proliferation; Cellular therapy; Muscular dystrophy; Neural stem cell

Indexed keywords

ALPHA ACTININ; CD31 ANTIGEN; DYSTROPHIN; NESTIN; TRANSCRIPTION FACTOR NKX2.5; TROPOMYOSIN; TROPONIN I; DIFFERENTIATION ANTIGEN; INTERMEDIATE FILAMENT PROTEIN; NERVE PROTEIN; UTRN PROTEIN, MOUSE; UTROPHIN;

AGE; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL FATE; CELL PROLIFERATION; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DUCHENNE MUSCULAR DYSTROPHY; ECHOCARDIOGRAPHY; HEART MUSCLE CELL; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEM CELL TRANSPLANTATION; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE; ANIMAL; AORTA; CELL CULTURE; CORONARY BLOOD VESSEL; DISEASE MODEL; GENETICS; HEART MUSCLE; HUMAN; METABOLISM; MOUSE MUTANT; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; STEM CELL;

AGE FACTORS; ANIMALS; ANTIGENS, DIFFERENTIATION; AORTA; CARDIOMYOPATHY, DILATED; CELL PROLIFERATION; CELLS, CULTURED; CORONARY VESSELS; DISEASE MODELS, ANIMAL; DYSTROPHIN; HUMANS; INTERMEDIATE FILAMENT PROTEINS; MICE; MICE, INBRED MDX; MICE, KNOCKOUT; MUSCULAR DYSTROPHY, DUCHENNE; MYOCARDIUM; MYOCYTES, CARDIAC; NEOVASCULARIZATION, PHYSIOLOGIC; NERVE TISSUE PROTEINS; STEM CELL TRANSPLANTATION; STEM CELLS; UTROPHIN;

MLCS; MLOWN;

EID: 84873472020     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2012-0107     Document Type: Article

References (87)

1. Emery AE. Population frequencies of inherited neuromuscular diseases: A world survey. Neuromuscul Disord 1991;1:19-29.
2. Spurney CF, Guerron AD, Yu Q et al. Membrane sealant Poloxamer P188 protects against isoproterenol induced cardiomyopathy in dystrophin deficient mice. BMC Cardiovasc Disord 2011;11:20-30.
3. Eagle M, Bourke J, Bullock R et al. Managing Duchenne muscular dystrophy: The additive effect of spinal surgery and home nocturnalventilation in improving survival. Neuromuscul Disord 2007;17:470-475.
4. Eagle M, Baudouin SV, Chandler C et al. Survival in Duchenne muscular dystrophy: Improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord 2002;12:926-929.
5. Nigro G, Comi LI, Politano L et al. The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int J Cardiol 1990;26:271-277.
6. Bushby K, Muntoni F, Bourke JP. 107th ENMC international workshop: The management of cardiac involvement in muscular dystrophy and myotonic dystrophy. 7th-9th June 2002, Naarden, The Netherlands. Neuromuscular Disord 2003;13:166-172.
7. Baxter P. Treatment of the heart in Duchenne muscular dystrophy. Dev Med Child Neurol 2006;48:163.
8. Duboc D, Meune C, Lerebours G et al. Effect of Perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J Am Coll Cardiol 2005;45:855-857.
9. Ramaciotti C, Heistein LC, Coursey M et al. Left ventricular function and response to Enalapril in patients with Duchenne muscular dystrophy during the second decade of life. Am J Cardiol 2006;98:825-827.
10. Duboc D, Meune C, Pierre B et al. Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years' follow-up. Am Heart J 2007;154:596-602.
11. Rhodes J, Margossian R, Darras BT et al. Safety and efficacy of carvedilol therapy for patients with dilated cardiomyopathy secondary to muscular dystrophy. Pediatr Cardiol 2008; 29:343-351.
12. Kajimoto H, Ishigaki K, Okumura K et al. Beta-blocker therapy for cardiac dysfunction in patients with muscular dystrophy. Circ J 2006; 70:991-994.
13. Viollet L, Thrush PT, Flanigan KM et al. Effects of angiotensin-converting enzyme inhibitors and/or beta blockers on the cardiomyopathy in Duchenne muscular dystrophy. Am J Cardiol 2012;110:98-102.
14. Ishikawa Y, Bach JR, Minami R. Cardioprotection for Duchenne's muscular dystrophy. Am Heart J 1999;137:895-902.
15. Jefferies JL, Eidem BW, Belmont JW et al. Genetic predictors and remodeling of dilated cardiomyopathy in muscular dystrophy. Circulation 2005;112:2799-2804.
16. Ogata H, Ishikawa U, Ishikawa Y et al. Beneficial effects of beta-blockers and angiotensin-converting enzyme inhibitors in Duchenne muscular dystrophy. J Cardiol 2009;53: 72-78.
17. Biggar WD, Harris VA, Eliasoph L et al. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord 2006;16:249-255.
18. Silversides CK, Webb GD, Harris et al. Effects of Deflazacort on left ventricular function in patients with Duchenne muscular dystrophy. Am J Cardiol 2003;91:769-772.
19. Markham LW, Spicer RL, Khoury PR et al. Steroid therapy and cardiac function in Duchenne muscular dystrophy. Pediatr Cardiol 2005;26:768-771.
20. Markham LW, Kinnett K, Wong BL et al. Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy. Neuromuscul Disord 2008;18: 365-370.
21. Houde S, Filiatrault M, Fournier A et al. Deflazacort use in Duchenne muscular dystrophy: An 8-year follow-up. Pediatr Neurol 2008; 38:200-206.
22. Yasuda S, Townsend D, Michele DE et al. Dystrophic heart failure blocked by membrane sealant poloxamer. Nature 2005;436:1025-1029.
23. Townsend D, Turner I, Yasudsa S et al. Chronic administration of membrane sealant prevents severe cardiac injury and ventriculardilatin in dystrophic dogs. J Clin Invest 2010; 120:1140-1150.
24. Piccolo G, Azan G, Tonin P et al. Dilated cardiomyopathy requiring cardiac transplantation as initial manifestation of Xp21 Becker type muscular dystrophy. Neuromuscul Disord 1994;4:143-146.
25. Saito M, Kawai H, Akaike M et al. Cardiac dysfunction with Becker muscular dystrophy. Am Heart J 1996;132:642-647.
26. Berko BA, Swift M. X-linked dilated cardiomyopathy. N Engl J Med 1987;316:1186-1191.
27. Towbin JA, Hejtmancik JF, Brink P et al. X-linked dilated cardiomyopathy: Molecular genetic evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus. Circulation 1993;87:1854-1865.
28. Townsend D, Blankinship MJ, Allen JM et al. Systemic administration of micro-dystrophin restores cardiac geometry and prevents dobutamine-induced cardiac pump failure. Mol Ther 2007;15:1086-1092.
29. Gregorevic P, Allen JM, Minami E et al. rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat Med 2006;12:787-789.
30. Harper S, Hauser MA, DelloRusso C et al. Modular flexibility of dystrophin: Implications for gene therapy of Duchenne muscular dystrophy. Nat Med 2002;8:253-261.
31. Bostick B, Yue Y, Long C et al. Cardiac expression of a mini-dystrophin that normalizes skeletal muscle force only partially restores heart function in aged Mdx mice. Mol Ther 2009;17:253-261.
32. Mendell JR, Rodino-Klapac LR, Rosales XQ et al. Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, Type 2D. Ann Neurol 2010;68: 629-638.
33. Mingozzi F, Hasbrouck NC, Basner E et al. Modulation of tolerance to the transgene product in a nonhuman primate model of AAV- mediated gene transfer to liver. Blood 2007; 110:2334-2341.
34. Mingozzi F, Meulenberg JJ, Hui DJ et al. AAV-1 mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood 2009; 114:2077-2086.
35. Wang Z, Storb R, Lee D et al. Immune responses to AAV in canine muscle monitored by cellular assays and noninvasive imaging. Mol Ther 2010;18:617-624.
36. Wu B, Xiao B, Cloer C et al. One-year treatment of morpholino antisense oligomer improves skeletal and cardiac muscle functions in dystrophic mdx mice. Mol Ther 2011;19: 576-583.
37. Berry SE, Liu J, Chaney EJ et al. Multipotential mesoangioblast stem cell therapy in the mdx/utrn/mouse model for Duchenne muscular dystrophy. Regen Med 2007;2:275-288.
38. Sampaolesi M, Blot S, D'Antona G et al. Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. Nature 2006;444: 574-579.
39. Koh GY, Soonpaa MH, Klug MG et al. Stable fetal cardiomyocyte grafts in the hearts of dystrophic mice and dogs. J Clin Invest 1995; 96:2034-2042.
40. Payne TR, Oshima H, Sakai R et al. Regeneration of dystrophin-expressing myocytes in the mdx heart by skeletal muscle stem cells. Gene Ther 2005;12:1264-1274.
41. Bridges LR. The association of cardiac muscle necrosis and inflammation with the degenerative and persistent myopathy of MDX mice. J Neurol Sci 1986;72:147-157.
42. Quinlan JG, Hahn HS, Wong BL et al. Evolution of the mdx mouse cardiomyopathy: Physiological and morphological findings. Neuromuscul Disord 2004;14:491-496.
43. Bostick B, Yue Y, Long C et al. Prevention of dystrophin-deficient cardiomyopathy in twenty-one-month-old carrier mice by mosaic dystrophin expression or complementary dystrophin-utrophin expression. Circ Res 2008; 102:121-130.
44. Tinsley JM, Potter AC, Phelps SR et al. Amelioration of the dystrophoic phenotype of mdx mice using a truncated utrophin transgene. Nature 1996;384:349-353.
45. Grady RM, Teng H, Nichol MC et al. Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: A model for Duchenne muscular dystrophy. Cell 1997;90:729-738.
46. Chun JL, O'Brien R, Berry SE. Cardiac dysfunction and pathology in the dystrophin and utrophin-deficient mouse during development of dilated cardiomyopathy. Neuromuscul Disord 2012;22:368-379.
47. Wang L, Kamath A, Frye J. Aorta-derived mesoangioblasts differentiate into oligodendrocytes by inhibition of the Rho kinase signaling pathway. Stem Cells Dev 2012;21:1069-1089.
48. Burkin DJ, Wallace GQ, Nicol KJ et al. Enhanced expression of the 7 1 integrin reduces muscular dystrophy and restores viability in dystrophic mice. J Cell Biol 2001;152: 1207-1218.
49. Odintsov B, Chun J, Mulligan J et al. 14.1 T whole body MRI for detection of mesoangioblast stem cells in a murine model of Duchenne muscular dystrophy. Magn Reson Med 2011; 66:1704-1714.
50. Odintsov B, Chun J, Berry SE. Whole body MRI followed by fluorescent microscopy analysis for detection of stem cells labeled with superparamagnetic iron oxide (SPIO) nanoparticles and DiI following intracardiac injection, skeletal muscle transplantation, or systemic delivery. In: Turksen K, ed. Methods in Molecular Biology, Imaging and Tracking Stem Cells: Methods and Protocols. New York, NY: Humana Press, Springer Science and Business Media, in press.
51. Holt P, Rhode EA, Kines H. Ventricular volumes and body weight in mammals. Am J Physiol 1968;215:704-715.
52. Menasché P. Stem cell therapy for chronic heart failure: Lessons from a 15-year experience. C R Biol 2011;334:489-496.
53. Torella D, Ellison GM, Méndez-Ferrer S et al. Resident human cardiac stem cells: Role in cardiac cellular homeostasis and potential for myocardial regeneration. Nat Clin Pract Cardiovasc Med 2006;3(suppl 1):S83-S89.
54. El-Helou V, Beguin PC, Assimakopoulos J et al. The rat heart contains a neural stem cell population; Role in sympathetic sprouting and angiogenesis. J Mol Cell Cardiol 2008;45:694-702.
55. El-Helou V, Dupuis J, Proulx C. Resident nestin neural-like cells and fibers are detected in normal and damaged rat myocardium. Hypertension 2005;46:1219-1225.
56. Scobioala S, Klocke R, Kuhlmann M et al. Up-regulation of nestin in the infarcted myocardium potentially indicates differentiation of resident cardiac stem cells into various lineages including cardiomyocytes. FASEB J 2008; 22:1021-1031.
57. Béguin P, El-Helou V, Assimakopoulos J et al. The phenotype and potential origin of nestin cardiac myocyte-like cells following infarction. J Appl Physiol 2009;107:1241-1248.
58. St. John Sutton MGSJ, Sharpe N. Left ventricular remodeling after myocardial infarction. Pathophysiol Ther Circul 2000;101;2981-2988.
59. Konstam MA, Kramer DG, Patel AR et al. Left ventricular remodeling in heart failure: Current concepts in clinical significance and assessment. JACC Cardiovasc Imaging 2011;4: 98-108.
60. White HD, Norris RM, Brown MA et al. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987;76:44-51.
61. Galvez BG, Sampaolesi M, Barbuti A et al. Cardiac mesoangioblasts are committed, selfrenewable progenitors, associated with small vessels of juvenile mouse ventricle. Cell Death Differ 2008;15:1417-1428.
62. Minasi MG, Riminucci M, De Angelis L et al. The meso-angioblast: A multipotent, selfrenewing cell that originates from the dorsal aorta and differentiates into most mesodermal tissues. Development 2002;129:2773-2783.
63. Galli D, Innocenzi A, Staszewsky L et al. Mesoangioblasts, vessel-associated multipotent stem cells repair the infarcted heart by multiple cellular mechanisms. Arterioscler Thromb Vasc Biol 2005;25:692-697.
64. Tedesco FS, Gerli MFM, Perani L et al. Transplantation of genetically corrected human iPSC-derived progenitors in mice with limb-girdle muscular dystrophy. Sci Transl Med 2012;4:140-89.
65. Katare J, Riu F, Mitchell K et al. Transplantation of human pericyte progenitor cells improves the repair of infarcted heart through activation of an angiogenic program involving micro-RNA-132. Circ Res 2011;109:894-906.
66. Young PP, Vaughan DE, Hatzopoulos AK. Biologic properties of endothelial progenitor cells and their potential for cell therapy. Prog Cardiovasc Dis 2007;49:421-429.
67. Reffelmann T, Dow JS, Dai W et al. Transplantation of neonatal cardiomyocytes after permanent coronary artery occlusion increases regional blood flow of infarcted myocardium. J Mol Cell Cardiol 2003;35:607-613.
68. Miike T, Sugino S, Ohtani Y et al. Vascular endothelial cell injury and platelet embolism in Duchenne muscular dystrophy at the preclinical stage. J Neurol Sci 1987;82:67-80.
69. Musch BC, Papapetropoulos TA, McQueen DA et al. A comparison of the structure of small blood vessels in normal, denervated and dystrophic human muscle. J Neurol Sci 1975;26:221-234.
70. Loufrani L, Matrougui K, Gorny D et al. Flow (shear stress)-induced endothelium-dependent dilation is altered in mice lacking the gene encoding for dystrophin. Circulation 2001;103:864-870.
71. Sato K, Yokota T, Ichioka S et al. Vasodilation of intramuscular arterioles under shear stress in dystrophin-deficient skeletal muscle is impaired through decreased nNOS expression. Acta Myologica 2008;27:30-36.
72. Sander M, Chavoshan B, Harris SA et al. Functional muscle ischemia in neuronal nitric oxide synthase-deficient skeletal muscle of children with Duchenne muscular dystrophy. Proc Natl Acad Sci USA 2000;97:13818-13823.
73. Messina S, Mazzeo A, Bitto A et al. VEGF overexpression via adeno-associated virus gene transfer promotes skeletal muscle regeneration and enhances muscle function in mdx mice. FASEB J 2007;21:3737-3746.
74. D'Amore PA, Brown RH, Ku PT et al. Elevated basic fibroblast growth factor in the serum of patients with Duchenne muscular dystrophy. Ann Neurol 1994;35:362-365.
75. Fang J, Shi G, Vaghy PL. Identification of the increased expression of monocyte chemoattractant protein-1, cathepsin S, UPIX-1, and other genes in dystrophin-deficient mouse muscles by suppression subtractive hybridization. J Cell Biochem 2000;79:164-172.
76. Porter JD, Guo W, Merriam AP et al. Persistent over-expression of specific CC class chemokines correlates with macrophage and T-cell recruitment in mdx skeletal muscle. Neuromuscul Disord 2003;13:223-235.
77. Toti P, Villanova M, Vatti R et al. Nerve growth factor expression in human dystrophic muscles. Muscle Nerve 2003;27:370-373.
78. Straino S, Germani A, Di Carlo A et al. Enhanced arteriogenesis and wound repair in dystrophin-deficient mdx mice. Circulation 2004;110:3341-3348.
79. Kachinsky AM, Dominov JA, Miller JB. Intermediate filaments in cardiac myogenesis: nestin in the developing mouse heart. J Histochem Cytochem 1995;43:843-847.
80. Tomita Y, Matsumura K, Wakamatsu Y et al. Cardiac neural crest cells contribute to the dormant multipotent stem cell in the mammalian heart. J Cell Biol 2005;170:1135-1146.
81. Mokry ́ J, Karbanová J, Filip S et al. Phenotypic and morphological characterization of in vitro oligodendrogliogenesis. Stem Cells Dev 2008;17:333-341.
82. Blau HM, Webster C, Pavlath GK. Defective myoblasts identified in Duchenne muscular dystrophy. Proc Natl Acad Sci USA 1983;80: 4856-4860.
83. Webster C, Blau HM. Accelerated agerelated decline in replicative life-span of Duchenne muscular dystrophy myoblasts: Implications for cell and gene therapy. Somat Cell Mol Genet 1990;16:557-565.
84. Kudryashova E, Kramerova I, Spencer MJ. Satellite cell senescence underlies myopathy in a mouse model of limb-girdle muscular dystrophy 2H. J Clin Invest 2012;122:1764-1776.
85. Cassano M, Berardi E, Crippa S et al. Alteration of cardiac progenitor cell potency in GRMD dogs. Cell Transplant 2012 [Epub ahead of print].
86. Sacco A, Mourkioti F, Tran R et al. Short telomeres and stem cell exhaustion model Duchenne muscular dystrophy in mdx/mTR mice. Cell 2010;143:1059-1071.
87. Wang JS, Shum-Tim D, Chedrawy E et al. The coronary delivery of marrow stromal cells for myocardial regeneration: Pathophysiologic and therapeutic implications. J Thorac Cardiovasc Surg 2001;122:699-705.